Effects of empagliflozin on cyclophosphamide-induced neurotoxicity in rats without diabetes.

IF 1.2 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Turkish Journal of Medical Sciences Pub Date : 2024-12-30 eCollection Date: 2025-01-01 DOI:10.55730/1300-0144.5943

Şerife Ezgi Doğan, Şerife Mehlika Kuşkonmaz, Pınar Celepli, Mehmet Şenes, Sema Hücümenoğlu, Cavit Çulha

{"title":"Effects of empagliflozin on cyclophosphamide-induced neurotoxicity in rats without diabetes.","authors":"Şerife Ezgi Doğan, Şerife Mehlika Kuşkonmaz, Pınar Celepli, Mehmet Şenes, Sema Hücümenoğlu, Cavit Çulha","doi":"10.55730/1300-0144.5943","DOIUrl":null,"url":null,"abstract":"Background/aim: The objective of this study was to evaluate the effects of empagliflozin on cyclophosphamide-induced neurotoxicity in rats.Materials and methods: A total of 32 male Wistar rats were separated into 4 groups with 8 rats in each: the control group, cyclophosphamide group, empagliflozin group, and cyclophosphamide plus empagliflozin group. At the end of the experiment the rats' brains were removed for biochemical analysis of oxidative stress parameters (malondialdehyde, total sulfhydryl, total oxidant status, and total antioxidant capacity) and histopathological analysis.Results: Total sulfhydryl levels were increased in the empagliflozin group and empagliflozin and cyclophosphamide group compared to the cyclophosphamide group but histopathological findings were not improved. Furthermore, when empagliflozin treatment was used coupled with cyclophosphamide, necrosis was significantly higher.Conclusion: Empagliflozin has no protective effect on cyclophosphamide neurotoxicity, although it may have neurotoxic effects. Clarification of the possible neurotoxic/neuroprotective effects of empagliflozin would be beneficial for diabetic cancer patients who are receiving cyclophosphamide chemotherapy and empagliflozin together.","PeriodicalId":23361,"journal":{"name":"Turkish Journal of Medical Sciences","volume":"55 1","pages":"65-71"},"PeriodicalIF":1.2000,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11913512/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkish Journal of Medical Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.55730/1300-0144.5943","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: The objective of this study was to evaluate the effects of empagliflozin on cyclophosphamide-induced neurotoxicity in rats.

Materials and methods: A total of 32 male Wistar rats were separated into 4 groups with 8 rats in each: the control group, cyclophosphamide group, empagliflozin group, and cyclophosphamide plus empagliflozin group. At the end of the experiment the rats' brains were removed for biochemical analysis of oxidative stress parameters (malondialdehyde, total sulfhydryl, total oxidant status, and total antioxidant capacity) and histopathological analysis.

Results: Total sulfhydryl levels were increased in the empagliflozin group and empagliflozin and cyclophosphamide group compared to the cyclophosphamide group but histopathological findings were not improved. Furthermore, when empagliflozin treatment was used coupled with cyclophosphamide, necrosis was significantly higher.

Conclusion: Empagliflozin has no protective effect on cyclophosphamide neurotoxicity, although it may have neurotoxic effects. Clarification of the possible neurotoxic/neuroprotective effects of empagliflozin would be beneficial for diabetic cancer patients who are receiving cyclophosphamide chemotherapy and empagliflozin together.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Turkish Journal of Medical Sciences 医学-医学：内科

CiteScore

4.60

自引率

4.30%

发文量

143

审稿时长

3-8 weeks

期刊介绍： Turkish Journal of Medical sciences is a peer-reviewed comprehensive resource that provides critical up-to-date information on the broad spectrum of general medical sciences. The Journal intended to publish original medical scientific papers regarding the priority based on the prominence, significance, and timeliness of the findings. However since the audience of the Journal is not limited to any subspeciality in a wide variety of medical disciplines, the papers focusing on the technical details of a given medical subspeciality may not be evaluated for publication.